AtriCure hails first-in-man implant of left atrial appendage occluder:
This article was originally published in Clinica
Executive Summary
AtriCure has, for the first time, implanted its CosGrove-Gillinov left atrial appendage (LAA) occlusion system into a patient. The LAA is a thumb-shaped area of the atrium that is prone to developing blood clots which can then migrate to other parts of the body. The product is a clip device designed to be implanted from outside the heart, thus avoiding contact with circulating blood and eliminating blood flow between the LAA and atria. Research has suggested that patients with atrial fibrillation are particularly prone to clot formation in the LAA, which some physicians believe is associated with AF-related strokes, claimed the West Chester, Ohio firm. The device was implanted during an open heart procedure by a team of doctors from the University of Zurich in Switzerland and Cleveland Clinic in Ohio.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.